This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Gastric Carcinoma Stage IV
and you are
over 20
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to identify the non-inferiority of the combination therapy of Capecitabine and Oxaliplatin compared with the combination therapy of Fluorouracil/Folinic acid and Oxaliplatin in patients with advanced gastric cancer.

Provided treatments

  • Drug: XELOX
  • Drug: FOLFOX

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01748851. The sponsor of the trial is Dong-A University Hospital and it is looking for 42 volunteers for the current phase.
Official trial title:
A Phase III Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Capecitabine and Oxaliplatin (XELOX) in Comparison to the Combination Therapy of Fluorouracil/Folinic Acid and Oxaliplatin (FOLFOX) in Patients With AGC